Calciphylaxis after renal transplant. Three clinical cases report

  • Rita Marcela Fortunato Unidad Renal, Hospital Universitario Fundación Favaloro, Buenos Aires
  • Héctor Emmanuel Arias Unidad Renal, Hospital Universitario Fundación Favaloro, Buenos Aires
  • Luis María Gutiérrez Unidad Renal, Hospital Universitario Fundación Favaloro, Buenos Aires
  • Fernando Amador Mos Unidad Renal, Hospital Universitario Fundación Favaloro, Buenos Aires
  • Pablo Miguel Raffaele Unidad Renal, Hospital Universitario Fundación Favaloro, Buenos Aires
Keywords: calciphylaxis, hypercalcemia, renal transplant

Abstract

Introduction: Calciphylaxis (CFX) is a syndrome characterized by deposition of calcium in the intima and media of vessels, intimal proliferation, fibrosis, luminal thrombosis, tissue ischemia and necrosis. Its initial report and subsequent descriptions were associated with chronic renal failure. There is little information regarding the possible effect of the recovery of renal function secondary to kidney transplantation in the incidence of this disease. Methods: Center retrospective study. We analyze in this report the three cases of patients who developed CFX after a renal transplant within a cohort of 448 kidney and kidney-pancreas transplant patients from January 1th 2001 to January 1th 2014 in our Hospital. Results: Three patients were found to have CFX. All of them had hypercalcemia (serum calcium average 11.5 mg/dl) at first year post transplant and 2 patients at diagnosis of CFX. PTHi in the three CFX patients was 2 pg/ml, 62,3pg/ml and 3561pg/ml respectively. Hypoalbuminemia was found in all patients. Two patients were diabetic. Only one patient was obese and under anticoagulation treatment. In all cases a biopsy provided the diagnosis of certainty for calciphylaxis. Median serum creatinine at diagnosis was 1.5 mg/dl (1.2 mg/dl 1.2 mg/dl and 2 mg/dl, respectively) and the average time between transplantation and calciphylaxis diagnosis was 32 months. In all cases, strict control of phosphorus and hypercalcemia and sodium IV thiosulfate treatment was performed. The evolution was successful in two patients, controlling blood calcium and improving cutaneous manifestations with preservation of renal function. Conclusions: CFX prevalence in a cohort of 448 kidney and kidney-pancreas transplant patients from 2001 to 2014 was 0.66%, less than reported in dialysis patients. Factors associated with CFX in our patients were hypercalcemia in the first year after renal transplant and at the time of the event, hypoalbuminemia, diabetes and disorders of the parathyroid gland. The persistence of hypercalcemia in the first year after renal transplant should be an element of high clinical suspicion of this complication in the kidney transplant recipients.

References

Selye H, Gentile G, Prioreschi P. Cutaneous molt induced by calciphylaxis in the rat. Science. 1961;134(3493):1876-7.

Nigwekar SU, Kroshinsky D, Nazarian RM, Goverman J, Malhotra R, Jackson VA, et al. Calciphylaxis: risk factors, diagnosis, and treatment. Am J Kidney Dis. 2015;66(1):133-46.

Nigwekar SU, Wolf M, Sterns RH, Hix JK. Calciphylaxis from nonuremic causes: a systematic review. Clin J Am Soc Nephrol. 2008;3(4):1139-43.

Picazo Sánchez M, Cuxart Pérez M, Sans Lorman R, Sardà Borroy C. Proximal calciphylaxis in a patient with liver and kidney transplantation. Nefrologia. 2009;29(5):489-90.

Angelis M, Wong LL, Myers SA, Wong LM. Calciphylaxis in patients on hemodialysis: a prevalence study. Surgery. 1997;122(6):1083-9.

Bhat S, Hegde S, Bellovich K, El-Ghoroury M. Complete resolution of calciphylaxis after kidney transplantation. Am J Kidney Dis. 2013;62(1):132-4.

Hanvesakul R, Silva MA, Hejmadi R, Mellor S, Ready AR, Cockwell P, et al. Calciphylaxis following kidney transplantation: a case report. J Med Case Rep. 2009;3:9297.

Budisavljevic MN, Cheek D, Ploth DW. Calciphylaxis in chronic renal failure. J Am Soc Nephrol. 1996;7(7):978-82.

Rogers NM, Chang SH, Teubner DJ, Coates PT. Hyperbaric oxygen as effective adjuvant therapy in the treatmentof distal calcific uraemic arteriolopathy. NDT Plus. 2008;1(4):244-9.

Schafer C, Heiss A, Schwarz A, Westenfeld R, Ketteler M, Floege J, et al. The serum protein alpha 2-Heremans-Schmid glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcification. J Clin Invest. 2003;112(3):357-66.

Torregrosa JV, Barros X. Management of hypercalcemia after renal transplantation. Nefrologia. 2013;33(6):751-7.

London GM, Marty C, Marchais SJ, Guerin AP, Metivier F, De Vernejoul MC. Arterial calcifications and bone histomorphometry in end-stage renal disease. J Am Soc Nephrol. 2004;15(7):1943-51.

Girotto JA, Harmon JW, Ratner LE, Nicol TL, Wong L, Chen H. Parathyroidectomy promotes wound healing and prolongs survival in patients with calciphylaxis from secondary hyperparathyroidism. Surgery. 2001;130(4):645-50.

Janigan DT, Hirsch DJ, Klassen GA, MacDonald AS. Calcified subcutaneous arterioles with infarcts of the subcutis and skin (“calciphylaxis”) in chronic renal failure. Am J Kidney Dis. 2000;35(4):588-97.

Salanova Villanueva L, Sánchez González MC, Sánchez Tomero JA, Sanz P. Successful treatment with sodium thiosulfate for calcific uraemic arteriolopathy. Nefrologia. 2011;31(3):366-8.

Cicone JS, Petronis JB, Embert CD, Spector DA. Successful treatment of calciphylaxis with intravenous sodium thiosulfate. Am J Kidney Dis. 2004;43(6):1104-8.

Published
2017-04-28
How to Cite
1.
Fortunato RM, Arias HE, Gutiérrez LM, Mos FA, Raffaele PM. Calciphylaxis after renal transplant. Three clinical cases report. Rev Nefrol Dial Traspl. [Internet]. 2017Apr.28 [cited 2024Jul.16];36(1):12-0. Available from: http://revistarenal.org.ar/index.php/rndt/article/view/51
Section
Original Article